These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28401744)

  • 1. FDG-PET in macrophage activation syndrome associated with systemic juvenile idiopathic arthritis.
    Shimizu M; Ikawa Y; Mizuta M; Takakura M; Inoue N; Nishimura R; Yachie A
    Pediatr Int; 2017 Apr; 59(4):509-511. PubMed ID: 28401744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of FDG-PET findings in the diagnosis of systemic juvenile idiopathic arthritis.
    Kanetaka T; Mori M; Nishimura K; Nozawa T; Kikuchi M; Sakurai N; Hara R; Yamazaki K; Yokota S
    Mod Rheumatol; 2016; 26(3):362-7. PubMed ID: 26417716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET assessment of disease activity in children with juvenile idiopathic arthritis.
    Tateishi U; Imagawa T; Kanezawa N; Okabe T; Shizukuishi K; Inoue T; Yokota S
    Pediatr Radiol; 2010 Nov; 40(11):1781-8. PubMed ID: 20523983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Takakura M; Shimizu M; Irabu H; Sakumura N; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Clin Immunol; 2019 Nov; 208():108252. PubMed ID: 31449879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
    Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Clin Exp Immunol; 2018 Mar; 191(3):349-355. PubMed ID: 28815559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
    Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Shimizu M; Nakagishi Y; Inoue N; Mizuta M; Ko G; Saikawa Y; Kubota T; Yamasaki Y; Takei S; Yachie A
    Clin Immunol; 2015 Oct; 160(2):277-81. PubMed ID: 26101092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of vascular endothelial homeostasis in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The dynamic roles of angiopoietin-1 and -2.
    Tasaki Y; Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Wada T; Yachie A
    Cytokine; 2016 Apr; 80():1-6. PubMed ID: 26908294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis.
    Reddy VV; Myles A; Cheekatla SS; Singh S; Aggarwal A
    Int J Rheum Dis; 2014 Mar; 17(3):261-7. PubMed ID: 24417800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
    Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Pediatr Res; 2020 Dec; 88(6):934-939. PubMed ID: 32184444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
    Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
    Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Davì S; Minoia F; Pistorio A; Horne A; Consolaro A; Rosina S; Bovis F; Cimaz R; Gamir ML; Ilowite NT; Kone-Paut I; Feitosa de Oliveira SK; McCurdy D; Silva CA; Sztajnbok F; Tsitsami E; Unsal E; Weiss JE; Wulffraat N; Abinun M; Aggarwal A; Apaz MT; Astigarraga I; Corona F; Cuttica R; D'Angelo G; Eisenstein EM; Hashad S; Lepore L; Mulaosmanovic V; Nielsen S; Prahalad S; Rigante D; Stanevicha V; Sterba G; Susic G; Takei S; Trauzeddel R; Zletni M; Ruperto N; Martini A; Cron RQ; Ravelli A;
    Arthritis Rheumatol; 2014 Oct; 66(10):2871-80. PubMed ID: 25044674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Bracaglia C; de Graaf K; Pires Marafon D; Guilhot F; Ferlin W; Prencipe G; Caiello I; Davì S; Schulert G; Ravelli A; Grom AA; de Min C; De Benedetti F
    Ann Rheum Dis; 2017 Jan; 76(1):166-172. PubMed ID: 27296321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.
    Minoia F; Davì S; Horne A; Demirkaya E; Bovis F; Li C; Lehmberg K; Weitzman S; Insalaco A; Wouters C; Shenoi S; Espada G; Ozen S; Anton J; Khubchandani R; Russo R; Pal P; Kasapcopur O; Miettunen P; Maritsi D; Merino R; Shakoory B; Alessio M; Chasnyk V; Sanner H; Gao YJ; Huasong Z; Kitoh T; Avcin T; Fischbach M; Frosch M; Grom A; Huber A; Jelusic M; Sawhney S; Uziel Y; Ruperto N; Martini A; Cron RQ; Ravelli A; ; ; ;
    Arthritis Rheumatol; 2014 Nov; 66(11):3160-9. PubMed ID: 25077692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sudden Hypotension and Increased Serum Interferon-γ and Interleukin-10 Predict Early Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis.
    Guo L; Xu Y; Qian X; Zou L; Zheng R; Teng L; Zheng Q; Leung Jung LK; Lu M
    J Pediatr; 2021 Aug; 235():203-211.e3. PubMed ID: 33581106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages.
    Shimizu M; Yachie A
    Cytokine; 2012 Oct; 60(1):226-32. PubMed ID: 22682876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case of systemic-onset juvenile idiopathic arthritis complicated with sepsis --usefulness of cytokine profile for the differentiation between macrophage activation syndrome and sepsis.
    Yokoyama T; Shimizu M; Ikeno I; Hashida Y; Fujita S; Shimura S; Hatasaki K; Shintani N; Yachie A
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(2):105-11. PubMed ID: 21628853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical utility of splenic fluorodeoxyglucose uptake for diagnosis and prognosis in patients with macrophage activation syndrome.
    Ahn SS; Hwang SH; Jung SM; Lee SW; Park YB; Yun M; Song JJ
    Medicine (Baltimore); 2017 Aug; 96(34):e7901. PubMed ID: 28834911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage activation syndrome as a complication of juvenile rheumatoid arthritis.
    An Q; Jin MW; An XJ; Xu SM; Wang L
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4322-4326. PubMed ID: 29077164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
    Schulert GS; Yasin S; Carey B; Chalk C; Do T; Schapiro AH; Husami A; Watts A; Brunner HI; Huggins J; Mellins ED; Morgan EM; Ting T; Trapnell BC; Wikenheiser-Brokamp KA; Towe C; Grom AA
    Arthritis Rheumatol; 2019 Nov; 71(11):1943-1954. PubMed ID: 31379071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.